Prevention and treatment of heterotopic ossification after spinal cord injury

J Spinal Cord Med. 2004;27(4):376-82. doi: 10.1080/10790268.2004.11753775.

Abstract

Background/objectives: Heterotopic ossification (HO) is a frequent, irreversible complication after spinal cord injury (SCI). The objective of this article is to explain the etiology of HO; present new advances in prevention, diagnosis, and management of this complication; and provide a suggested algorithm for clinical management.

Etiology: Although still hypothetical, trauma and overexpression of bone morphogenic protein(s) in traumatized soft tissue appear to play important roles as initiating factors of HO.

Prevention: Preventive use of nonsteroidal antiinflammatory agents (NSAIDs) reduces the incidence of HO by a magnitude of 2 to 3.

Management: Early determination of serum creatine phosphokinase may have a diagnostic value in predicting the onset and severity of HO, and an NSAID may be added to etidronate therapy in the initial inflammatory phase of HO formation until C-reactive protein levels return to normal range. Surgery is indicated in a subset of patients, and a regimen that includes radiation therapy may prevent postoperative recurrence.

Conclusion: Significant progress has been made in the early prevention and management of HO. Further studies are needed to elucidate the etiology.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Drug Therapy, Combination
  • Etidronic Acid / therapeutic use
  • Humans
  • Ossification, Heterotopic / etiology
  • Ossification, Heterotopic / prevention & control*
  • Ossification, Heterotopic / surgery
  • Ossification, Heterotopic / therapy*
  • Spinal Cord Injuries / complications*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Etidronic Acid